Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies.

To address the scarcity of direct comparison of botulinum neurotoxin serotypes activity on smooth versus striatal muscle, we have studied the action of BoNT/A1 and BoNT/B1 on ex vivo preparations of both muscle types. We have set up and characterized a model of neurogenic contractions in the isolated mouse bladder, and used this model to explore the effects of the two serotypes on contractions evoked by electrical field stimulation. Both toxins were also tested in the mouse phrenic nerve hemidiaphragm assay, to compare their potency in smooth versus striated muscle.

Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.

The 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17beta-HSD type 1 enzyme (17beta-HSD1) catalyzes the reduction of estrone (E1) to estradiol and is expressed in malignant breast cells. Inhibitors of this enzyme thus have potential as treatments for hormone dependent breast cancer.

Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.

A series of 4-arylimidazole carbamates was synthesized and their binding affinities to the site-2 sodium (Na+) channel were determined. SAR studies led to the identification of compound 10, a potent Na+ channel blocker which was efficacious in pain models in vivo.

Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.

A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in cancer progression. Here, we characterize the new imidazo-pyrazine derivative BIM-46174, which acts as a selective inhibitor of heterotrimeric G-protein complex. BIM-46174 prevents the heterotrimeric G-protein signaling linked to several GPCRs mediating (a) cyclic AMP generation (Galphas), (b) calcium release (Galphaq), and (c) cancer cell invasion by Wnt-2 frizzled receptors and high-affinity neurotensin receptors (Galphao/i and Galphaq).

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

BN80927 belongs to a novel family of camptothecin analogs, the homocamptothecins, developed on the concept of topoisomerase I (Topo I) inhibition and characterized by a stable seven-membered beta-hydroxylactone ring. Preclinical data reported here show that BN80927 retains Topo I poisoning activity in cell-free assay (DNA relaxation) as well as in living cells, in which in vivo complexes of topoisomerase experiments and quantification of DNA-protein-complexes stabilization, have confirmed the higher potency of BN80927 as compared with the Topo I inhibitor SN38. In addition, BN80927 inhibits Topo II-mediated DNA relaxation in vitro but without cleavable-complex stabilization, thus indicating catalytic inhibition.

2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators.

A series of 2-alkyl-4-arylimidazoles were prepared and their binding affinities to the site-2 sodium (Na+) channel were determined. SAR studies led to highly potent Na+ channel blockers.

A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

We report the synthesis and pharmacological evaluation of a novel homocamptothecin (hCPT) derivative, 12-Cl-hCPT, which contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone found in camptothecin (CPT) and bears a chloro substituent at position 12. The capacity of 12-Cl-hCPT to inhibit DNA topoisomerase I was compared with that of SN-38, the active metabolite of the clinically used antitumour prodrug CPT-11. In the DNA relaxation assay, 12-Cl-hCPT proved to be slightly more potent than SN-38 at stimulating the formation of nicked plasmid DNA molecules.

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

BN 80915, a lead compound of the homocamptothecin (hCPT) family, has entered clinical trials. BN 80915 is a difluoro-hCPT where the six-membered alpha-hydroxylactone ring of camptothecin (CPT) is replaced by a seven-membered beta-hydroxylactone ring. Preclinical data reported here show that in spite of the modification to the crucial E-ring of CPTs, BN 80915 retains topoisomerase I poisoning activity as shown in living HT29 cells as well as in cell-free assays, where BN 80915 always performs better than SN-38 or TPT.

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone. Combining pronounced inhibitory activity of topoisomerase I (Topo I) with enhanced plasma stability, hCPT constitutes an attractive template for the elaboration of new anticancer agents. Fluorinated hCPT analogues, prepared in enantiomerically pure form, were assayed by their stimulation of Topo I-mediated DNA cleavage.

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

Homocamptothecin (hCPT) contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone ring found in camptothecin and its tumor active analogues, including topotecan and irinotecan. The homologation of the lactone E-ring reinforces the stability of the lactone, thus reducing considerably its conversion into a carboxylate form which is inactive. We have recently shown that hCPT is much more active than the parent compound against a variety of tumor cells in vitro and in xenograft models, suggesting that a highly reactive lactone is not essential for topoisomerase I-mediated anticancer activity [Lesueur-Ginot et al.

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

BN 80927, a novel homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation and shows pronounced cytotoxicity against HT29, SKOV-3, DU145 and MCF7 human tumor cell lines.

Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.

Nicotine exerts antinociceptive effects by interacting with one or more of the subtypes of nicotinic acetylcholine receptors (nAChRs) that are present throughout the neuronal pathways that respond to pain. To identify the particular subunits involved in this process, we generated mice lacking the alpha4 subunit of the neuronal nAChR by homologous recombination techniques and studied these together with previously generated mutant mice lacking the beta2 nAChR subunit. Here we show that the homozygous alpha4-/- mice no longer express high-affinity [3H]nicotine and [3H]epibatidine binding sites throughout the brain.

The early expression of Rev-erbbeta occurs in the developing nervous system of mouse embryo.

The orphan ligand nuclear receptor Rev-erbbeta acts in vitro as a negative regulator of transcription. However, its precise physiological role is still unknown. As a first attempt to better understand its biological function, we have studied the distribution and the localization of the Rev-erbbeta mRNA transcripts in different mouse embryonal carcinoma cell lines, in mouse embryos and adult tissues.

Developmental regulation of membrane traffic organization during synaptogenesis in mouse diaphragm muscle.

In innervated adult skeletal muscles, the Golgi apparatus (GA) displays a set of remarkable features in comparison with embryonic myotubes. We have previously shown by immunocytochemical techniques, that in adult innervated fibers, the GA is no longer associated with all the nuclei, but appears to be concentrated mostly in the subneural domain under the nerve endings in chick (Jasmin, B. J.

Developmental regulation of acetylcholinesterase transcripts in the mouse diaphragm: alternative splicing and focalization.

We studied the splicing and compartmentalization of acetylcholinesterase (AchE) mRNAs during muscle differentiation in the mouse, both in vitro and in vivo. We used the polymerase chain reaction (PCR) to analyse AChE mRNAs in cultures of the myogenic C2 and Sol8 cell lines, and in the developing diaphragm, from embryonic day 14 (E14). We characterized three types of alternatively spliced AChE mRNAs, encoding catalytic subunits that differ by their C-terminal regions (R, H and T).

New antineoplastic aza-phospholipids - synthesis, in-vitro cytotoxicity and differential cellular-sensitivity against 70 human tumor-cell lines.

The in vitro cytotoxicity and differential cellular sensitivity of three new synthetic anti-neoplastic aza-phospholipids has been determined in the National Cancer Institute's (NCI) primary antitumor drug screen. Based on a disease-oriented strategy, this screen incorporates seventy human cell lines representing leukemia, ovarian, brain, melanoma, colon, renal, lung, prostate and breast cancers. The analysis of the GI50 values obtained for each aza-derivative has revealed a differential cellular sensitivity among the cell lines examined.

Compartmentalized expression of the alpha- and gamma-subunits of the acetylcholine receptor in recently fused myofibers.

The mRNAs encoding the subunits of the acetylcholine receptor are clustered at the level of the neuromuscular junction in adult muscle fibers. We have followed the distribution of the mRNAs encoding the alpha- and gamma-subunits during development of the diaphragm muscle in the mouse by whole-mount in situ hybridization. We show that the mRNAs encoding both subunits display a nonhomogeneous distribution as early as Day 13.

Localization of mRNAs coding for CMD1, myogenin and the alpha-subunit of the acetylcholine receptor during skeletal muscle development in the chicken.

Myogenin and CMD1, the chicken homologue of MyoD, transactivate the promoter of the alpha-subunit of the acetylcholine receptor (AChR) in chicken fibroblasts. The expression of these three genes was followed by in situ hybridization. In two-day-old embryos the CMD1 gene is expressed shortly before the AChR alpha-subunit and the myogenin genes.

Occurrence of neuropeptide K-like immunoreactivity in ventral horn cells of the chicken spinal cord during development.

The possible occurrence of NPK-LI in the ventral horns of the embryonic chicken spinal cord was investigated by means of the indirect immunofluorescence method. The results showed a transient appearance of NPK-LI in cells of the lateral motor column between day 5 of incubation and hatching. After this they disappeared and in the ventral horns NPK-LI remained only in fibers.

Survival in vitro of motoneurons identified or purified by novel antibody-based methods is selectively enhanced by muscle-derived factors.

Motoneurons were identified in vitro by a new method using the SC1 monoclonal antibody. They constituted up to 30% of total neurons in cultures of whole spinal cord from 4.5-day chicken embryos, and survived for at least 5 days in the presence of muscle extract, but not in its absence.

Two adjacent MyoD1-binding sites regulate expression of the acetylcholine receptor alpha-subunit gene.

Several genes encoding putative myogenic regulatory factors have been isolated on the basis of their ability to convert nonmuscle cells into myoblasts. Four of these genes code for nuclear proteins that belong to a larger family characterized by a conserved helix-loop-helix motif required for DNA-binding and dimerization. At least one protein, MyoD1, can function as a transcription factor and activate muscle-specific genes during differentiation.

Immunoreactive Calcitonin Gene-Related Peptide, Vasoactive Intestinal Polypeptide, and Somatostatin in Developing Chicken Spinal Cord Motoneurons.

The distribution of calcitonin gene-related peptide (CGRP)-, vasoactive intestinal polypeptide (VIP)-, and somatostatin (SOM)-like immunoreactivities (-LI) in neurons of the spinal cord of developing chickens was characterized by use of the indirect immunofluorescence technique, and the findings related to a possible role for these peptides in the development of muscles and motor endplates. CGRP-LI in presumptive motoneurons of the ventral horn was first observed at embryonic day 6. During the following days the number of CGRP-immunoreactive (IR) cells increased reaching high numbers between days 12 and 18 of incubation, and thereafter decreasing in numbers until hatching.

Existence and coexistence of calcitonin gene-related peptide, vasoactive intestinal polypeptide- and somatostatin-like immunoreactivities in spinal cord motoneurons of developing embryos and post-hatch chicks.

By use of immunocytochemical methods, it is shown that immunoreactive calcitonin gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) and somatostatin (SOM) are present in motoneurons in the chicken spinal cord. While CGRP-like immunoreactivity (LI) is present in numerous motoneurons both before and after hatching, SOM- and VIP-LI markedly decline at the end of the embryonic period. Evidence is also provided for coexistence of some of these peptides in certain spinal motoneurons.